Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Hum Genet ; 138(4): 293-305, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30840129

ABSTRACT

The understanding that differences in biological epistasis may impact disease risk, diagnosis, or disease management stands in wide contrast to the unavailability of widely accepted large-scale epistasis analysis protocols. Several choices in the analysis workflow will impact false-positive and false-negative rates. One of these choices relates to the exploitation of particular modelling or testing strategies. The strengths and limitations of these need to be well understood, as well as the contexts in which these hold. This will contribute to determining the potentially complementary value of epistasis detection workflows and is expected to increase replication success with biological relevance. In this contribution, we take a recently introduced regression-based epistasis detection tool as a leading example to review the key elements that need to be considered to fully appreciate the value of analytical epistasis detection performance assessments. We point out unresolved hurdles and give our perspectives towards overcoming these.


Subject(s)
Data Interpretation, Statistical , Epistasis, Genetic/physiology , Genome-Wide Association Study/statistics & numerical data , Culture , False Positive Reactions , Genetic Testing/methods , Genetic Testing/statistics & numerical data , Genome-Wide Association Study/methods , Humans , Polymorphism, Single Nucleotide
2.
Aliment Pharmacol Ther ; 47(3): 346-355, 2018 02.
Article in English | MEDLINE | ID: mdl-29226370

ABSTRACT

BACKGROUND: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD). AIM: To compare outcome, pharmacokinetics and immunogenicity of treatment intensification strategies in patients with CD who lost clinical response to IFX. METHODS: A retrospective cohort study was conducted, including 103 patients with CD who lost clinical response during IFX maintenance therapy and therefore received a double dose IFX (10 mg/kg) and/or a next infusion after a shortened interval. IFX and ATI concentrations were measured in consecutive trough samples, just before (T0) and after (T+1) treatment intensification. RESULTS: Clinical response (physicians' global assessment) and biological response and remission (CRP) were restored in 63%, 42% and 24% of patients (evaluated at T+1). Treatment intensification increased IFX trough concentrations from 1.2 µg/mL [0.3-3.6] at T0 to 3.6 µg/mL [0.5-10.2] at T+1 (P < .0001). Using a drug tolerant assay, ATI were detected in the T0 sample of 47% of patients. ATI negatively impacted the achieved IFX trough concentration (Spearman r -0.57, P < .0001) and the probability of clinical response (P = 0.034) at T+1. When ATI were quantifiable but <282 ng/mL eq. at T0, combined interval shortening and dose doubling was more effective for restoring therapeutic IFX trough concentrations (≥3 µg/mL at T+1) than dose doubling alone, which in turn was more effective than interval shortening alone (P < .001). CONCLUSION: Antibodies towards infliximab can guide clinical decision-making on treatment intensification.


Subject(s)
Antibodies/blood , Biomarkers, Pharmacological/blood , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Infliximab/administration & dosage , Infliximab/immunology , Adolescent , Adult , Antibodies/analysis , Biomarkers, Pharmacological/analysis , Crohn Disease/immunology , Crohn Disease/metabolism , Dose-Response Relationship, Drug , Drug Dosage Calculations , Drug Tolerance , Female , Gastrointestinal Agents/administration & dosage , Gastrointestinal Agents/immunology , Humans , Infliximab/pharmacokinetics , Male , Middle Aged , Prognosis , Retrospective Studies , Treatment Outcome , Young Adult
4.
Dis Esophagus ; 27(8): 726-31, 2014.
Article in English | MEDLINE | ID: mdl-24118437

ABSTRACT

Impedance baseline is a new parameter recently related to esophageal integrity. The aim of this study was to assess the effect of different factors on impedance baseline in pediatric patients. We analyzed the impedance baseline of 800 children with symptoms of gastroesophageal reflux. Mean impedance baseline was automatically calculated throughout 24-hour tracings. The presence of different age groups and of esophagitis was evaluated. Unpaired t-test, Spearman rank correlation, polynomial, and regression plot were used for statistical analysis. Age-related percentile curves were created. We considered a P-value<0.05 as statistically significant. Impedance baseline was significantly (P<0.001) lower in younger compared to older children up to 48 months. The mean increase of baseline per month was much higher in the first 36 months of life (47.5 vs. 2.9 Ohm in Channel 1 and 29.9 vs. 2.3 Ohm in Channel 6, respectively) than in older ages. Patients with esophagitis showed significantly decreased impedance baseline (P<0.05). Infants (especially in the first months of life) and young children present a significantly lower impedance baseline compared to older children both in proximal and distal esophagus. The presence of esophagitis may also determine a decreased impedance baseline regardless of the age of the patients.


Subject(s)
Esophagitis/physiopathology , Esophagus/physiopathology , Adolescent , Age Factors , Child , Child, Preschool , Electric Impedance , Esophageal pH Monitoring , Esophagitis/diagnosis , Esophagoscopy , Female , Gastroesophageal Reflux/diagnosis , Humans , Infant , Infant, Newborn , Male
5.
Hum Immunol ; 74(12): 1649-55, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23994582

ABSTRACT

The toll-like receptor (TLR) family maintains pulmonary homeostasis by pathogen recognition, clearance and regulation of inflammation. Genes affecting inflammation response play a key role in modifying Cystic fibrosis (CF) lung disease severity. We assessed the impact of single nucleotide polymorphisms (SNPs) of TLR genes (TLR1 to TLR10, CD14, lipopolyssacharide-binding protein (LBP)) on lung function in CF patients. Each SNP was tested for time-dependent effect on FEV1, using six genetic models. In addition, we investigated associations between SNP genotypes and extreme subject specific slopes of FEV1 decline. Variant alleles of polymorphisms of TLR2 rs1898830, rs5743708, and rs3804100 demonstrated a consistent association with lung disease severity (p = 0.008, p = 0.006 and p = 0.029 respectively). Patients homozygous for variant C allele of TLR5 polymorphism rs5744174 are more frequently associated with extreme fast FEV1 decline (OR: 20 (95% Confidence Interval:1.85-216.18)). Patients homozygous AA for TLR1 polymorphism rs5743551 are more frequently associated with faster decline of FEV1 compared to heterozygous genotype (OR:7.33 (95% CI:1.63-33.11). Our findings indicate that variations in TLR1, TLR2 and TLR5 genes may influence CF lung function decline. Further functional analysis is required to provide new insights into the pathogenesis of TLRs in CF lung disease severity.


Subject(s)
Cystic Fibrosis/genetics , Cystic Fibrosis/physiopathology , Forced Expiratory Volume , Polymorphism, Single Nucleotide , Toll-Like Receptors/genetics , Adolescent , Adult , Alleles , Case-Control Studies , Child , Child, Preschool , Cystic Fibrosis/metabolism , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Female , Genetic Association Studies , Humans , Male , Phenotype , Signal Transduction , Toll-Like Receptors/metabolism , Young Adult
6.
J Crohns Colitis ; 7(11): e588-98, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23664896

ABSTRACT

AIM: A Belgian registry for pediatric Crohn's disease, BELCRO, was created. This first report aims at describing disease presentation and phenotype and determining associations between variables at diagnosis and registration in the database. METHODS: Through a collaborative network, children with previously established Crohn's disease and newly diagnosed children and adolescents (under 18 y of age) were recruited over a 2 year period. Data were collected by 23 centers and entered in a database. Statistical association tests analyzed relationships between variables of interest at diagnosis. RESULTS: Two hundred fifty-five patients were included. Median age at diagnosis was 12.5 y (range: 1.6-18 y); median duration of symptoms prior to diagnosis was 3 m (range: 1-12 m). Neonatal history and previous medical history did not influence disease onset nor disease behavior. Fifty three % of these patients presented with a BMI z-score < -1. CRP was an independent predictor of disease severity. Steroids were widely used as initial treatment in moderate to severe and extensive disease. Over time, immunomodulators and biological were prescribed more frequently, reflecting a lower prescription rate for steroids and 5-ASA. A positive family history was the sole significant determinant for earlier use of immunosuppression. CONCLUSION: In Belgium, the median age of children presenting with Crohn's disease is 12.5 y. Faltering growth, extensive disease and upper GI involvement are frequent. CRP is an independent predictive factor of disease activity. A positive family history appears to be the main determinant for initial treatment choice.


Subject(s)
Crohn Disease/diagnosis , Crohn Disease/epidemiology , Registries , Adolescent , Age Distribution , Age of Onset , Anti-Inflammatory Agents/therapeutic use , Belgium/epidemiology , Child , Child, Preschool , Crohn Disease/drug therapy , Disease Progression , Drug Therapy, Combination , Humans , Immunosuppressive Agents , Infant , Logistic Models , Monitoring, Physiologic/methods , Multivariate Analysis , Prevalence , Prognosis , Risk Assessment , Severity of Illness Index , Sex Distribution , Statistics, Nonparametric
7.
Public Health Genomics ; 16(6): 305-12, 2013.
Article in English | MEDLINE | ID: mdl-24503591

ABSTRACT

BACKGROUND: Large-scale international collaboration is essential to decipher relevant information in the context of omics-scale interrogations in cancer research. This is even more important for rare and fatal diseases like pancreas cancer (PC). METHODS: The COST Action BM1204 is a unique platform to facilitate the collaboration of a broad range of European and international PC multidisciplinary research groups in order to: (1) integrate knowledge and experience in a multidisciplinary way 'from cell to society', (2) promote the application of uniform study tools and protocols, (3) foster their optimal use by early-stage researchers, (4) enhance the mobility and training of researchers, and (5) disseminate the results produced to the broader society. RESULTS: This Action will develop novel interdisciplinary tools for collaborative research to improve our understanding of PC and its prevention, diagnosis and treatment. It also aims to answer questions related to the etiology, early detection, evidence-based and personalized treatment, and health management for PC. Furthermore, the Action will contribute to new insights into PC personalized medicine and beyond as well as to the understanding of complex and rare diseases taking PC as a best practice example. The Action aims at attracting young scholars across a range of disciplines in collaboration with more experienced researchers and enhancing active European participation in the international scenario of PC research. CONCLUSION: The ultimate aim is to foster PC research in Europe and to coordinate this effort with other international initiatives to reduce disease mortality.


Subject(s)
Biomedical Research , Information Dissemination , International Cooperation , Pancreatic Neoplasms , Public Health , Translational Research, Biomedical , Europe , Humans , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/therapy , Rare Diseases/diagnosis , Rare Diseases/therapy
8.
Hum Immunol ; 73(11): 1175-83, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22940091

ABSTRACT

Genes of innate immunity may be involved in early onset of chronic Pa (Pseudomonas aeruginosa) colonization (cPaC) in cystic fibrosis (CF) patients. We studied 19 single nucleotide polymorphisms (SNPs) in 5 genes coding for proteins of the lectin complement pathway: MBL2 (Mannose binding lectin 2), MASP 1, 2, 3 (MBL-associated serine Protease) and FCN 1, 2 (Ficolin) gene in 96 CF patients. Association survival analysis using different genetic models was performed looking for an association between SNPs and age at onset of cPaC. CF patients who are MBL deficient are earlier chronic Pa colonized compared to MBL sufficient patients. Also patients with MBL2 genotype YO/YO, YO/XA, XA/XA, YA/YO and YA/XA are earlier chronic Pa colonized. CF patients heterozygous or homozygous for mutant alleles of two linked SNPs in the FCN1 gene (rs2989727 and rs1071583) are earlier colonized with Pa. Similarly, earlier onset of Pa colonization is seen in CF patients heterozygous for linked SNPs of FCN2 gene (rs7865453 and rs7851696) and MASP3 gene (rs7851696). Variants in MBL2, FCN1, FCN2 and MASP3 genes are significantly associated with earlier onset of chronic P. aeruginosa colonization.


Subject(s)
Complement Pathway, Mannose-Binding Lectin/genetics , Cystic Fibrosis/genetics , Cystic Fibrosis/immunology , Pseudomonas aeruginosa/immunology , Adolescent , Adult , Alleles , Child , Complement Pathway, Mannose-Binding Lectin/immunology , Cystic Fibrosis/microbiology , Cystic Fibrosis/mortality , Female , Genotype , Humans , Lectins/genetics , Male , Mannose-Binding Lectin/blood , Mannose-Binding Lectin/genetics , Mannose-Binding Protein-Associated Serine Proteases/genetics , Middle Aged , Polymorphism, Single Nucleotide , Pseudomonas Infections/immunology , Pseudomonas Infections/microbiology , Young Adult , Ficolins
9.
Acta Paediatr ; 101(5): 494-6, 2012 May.
Article in English | MEDLINE | ID: mdl-22226330

ABSTRACT

AIM: To prospectively evaluate the effects of oral domperidone on the QTc interval in infants. METHODS: Infants (0-1 year) with a diagnosis of gastro-oesophageal reflux (GOR) disease were included. A 12-lead electrocardiography (ECG) was performed in all infants at baseline and 1 h after the intake of domperidone after 7-14 days; the corrected QTc interval was calculated by one investigator (MV) according to Bazett's formula. RESULTS: Forty-five infants were enrolled in this study. The mean gestational age was of 38.6 weeks (35.5-42.0), and the mean age at the start of domperidone was 75.3 days (19-218 days). No statistically significant difference in corrected QTc was observed between baseline and the second ECG (0.389 ± 0.02 vs. 0.397 ± 0.31; p 0.130)). A trend was observed regarding gender: Although there was no difference in QTc change in girls (p 0.622), there was a strong trend in boys (p 0.051). Two infants (both boys) had a clinically significant QTc prolongation (> 460 msec) without symptoms. The Spearman correlation test showed no relation between the QTc change and age (r: -0.05822; p 0.7284). There was no relation between domperidone dosage and QTc change. CONCLUSION: Overall, the group-analysis showed no statistical significant difference in QTc duration induced by domperidone. However, 2/45 (4.4%) infants had a prolonged QTc interval (> 460 msec) induced by domperidone. As a consequence, QTc measurement should be recommended in routine in infants when domperidone is started.


Subject(s)
Antiemetics/pharmacology , Domperidone/pharmacology , Electrocardiography/drug effects , Female , Gastroesophageal Reflux/drug therapy , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Time Factors
10.
Acta Gastroenterol Belg ; 75(4): 425-31, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23402086

ABSTRACT

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD.


Subject(s)
Antibodies, Monoclonal , Crohn Disease , Drug Monitoring , Drug-Related Side Effects and Adverse Reactions , Withholding Treatment/statistics & numerical data , Adolescent , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/economics , Belgium/epidemiology , Child , Cost of Illness , Crohn Disease/drug therapy , Crohn Disease/economics , Crohn Disease/epidemiology , Drug Monitoring/methods , Drug Monitoring/statistics & numerical data , Drug-Related Side Effects and Adverse Reactions/classification , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Gastrointestinal Agents/administration & dosage , Gastrointestinal Agents/adverse effects , Gastrointestinal Agents/economics , Humans , Infliximab , Infusions, Intravenous , Male , Medication Therapy Management , Pharmacovigilance , Treatment Outcome
11.
Gut ; 61(4): 528-34, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21708824

ABSTRACT

BACKGROUND: Haptoglobin (Hp) is a haemoglobin-binding protein with immunomodulatory properties. Its gene (16q22) harbours a common polymorphism with two different alleles: Hp1 and Hp2. Genotype Hp22 has been shown to be over-represented in different immune diseases. Results in Crohn's disease (CD) are contradictory. AIMS: To determine whether Hp plays a role in inflammatory bowel disease, both genetically and functionally. METHODS: 1061 patients with CD, 755 with ulcerative colitis (UC) and 152 with primary sclerosing cholangitis, as well as 452 healthy controls, were genotyped using touch-down PCR. To confirm association results, 464 CD trios and 151 UC trios were genotyped. Serum Hp concentrations were determined in 62 individuals of different genotype. Colitis was induced in mice with dextran sulphate sodium (DSS) and oxazolone (Oxa). Cytokine production was evaluated by mRNA quantification in colonic tissue and ELISA on supernatants of mesenteric lymph node cells. RESULTS: Prevalence of Hp2 was higher in CD and UC than in controls. In the confirmatory cohorts, Hp2 was over-transmitted to the affected offspring. Serum Hp concentrations were higher in individuals with genotypes Hp11 and Hp21 than in those with Hp22 (1.38 vs 0.89 g/l). DSS- and Oxa-induced colitis were more severe in Hp-deficient mice than in control mice and accompanied by higher concentrations (although not statistically significantly different) of tissue mRNA for cytokines. Interleukin-17 production was significantly higher in the presence of Hp-deficient serum compared with wild-type serum. CONCLUSIONS: The Hp gene may play a role in susceptibility to inflammatory bowel disease. Its implication in other immune diseases underscores the common pathways between these diseases. Experimental models of colitis showed that Hp has a protective role in inflammatory colitis, most likely by inhibiting the production of Th1 and Th17 cytokines.


Subject(s)
Haptoglobins/genetics , Inflammatory Bowel Diseases/genetics , Polymorphism, Genetic , Adult , Animals , Cholangitis, Sclerosing/genetics , Cholangitis, Sclerosing/metabolism , Colitis/chemically induced , Colitis/genetics , Colitis/metabolism , Colitis, Ulcerative/genetics , Colitis, Ulcerative/metabolism , Colon/metabolism , Crohn Disease/genetics , Crohn Disease/metabolism , Cytokines/biosynthesis , Disease Models, Animal , Female , Genetic Predisposition to Disease , Genotype , Haptoglobins/deficiency , Haptoglobins/metabolism , Humans , Inflammation Mediators/metabolism , Inflammatory Bowel Diseases/metabolism , Male , Mice , Mice, Knockout , Young Adult
12.
Stat Med ; 30(18): 2201-21, 2011 Aug 15.
Article in English | MEDLINE | ID: mdl-21590702

ABSTRACT

With the establishment of large consortiums of researchers, genome-wide association (GWA) studies have become increasingly popular and feasible. Although most of these association studies focus on unrelated individuals, a lot of advantages can be exploited by including families in the analysis as well. To overcome the additional genotyping cost, multi-stage designs are particularly useful. In this article, I offer a perspective view on genome-wide family-based association analyses, both within a model-based and model-free paradigm. I highlight how multi-stage designs and analysis techniques, which are quite popular in clinical epidemiology, can enter GWA settings. I furthermore discuss how they have proven successful in reducing analysis complexity, and in overcoming one of the most cumbersome statistical hurdles in the genome-wide context, namely controlling increased false positives due to multiple testing.


Subject(s)
Genome, Human , Genome-Wide Association Study/methods , Models, Genetic , Quantitative Trait Loci , Family , Humans
13.
Allergy ; 65(7): 875-82, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20028371

ABSTRACT

BACKGROUND: High levels of total and allergen-specific IgE levels are a key feature in allergic diseases. The high-affinity receptor for IgE, which is composed of one alpha (FCER1A), one beta (FCER1B), and two gamma (FCER1G) subunits, represents the central receptor of IgE-induced reactions. In a genome-wide association scan, we recently identified associations between functional FCER1A variants and total serum IgE levels. Previous studies had reported linkage and association of FCER1B variants with IgE and atopic traits. The FCER1G gene has not yet been investigated with regard to atopy. Filaggrin (FLG) is the strongest known risk gene for eczema, in particular the allergic subtype of eczema. METHODS: We investigated the association of FCER1A, FCER1B, and FCER1G variants with IgE in a large population-based cohort (n = 4261) and tested for epistatic effects using the model-based multifactor dimensionality reduction (MB-MDR) method. In addition, we investigated a potential interaction between FLG and FCER1A variants in a large collection of eczema cases (n = 1018) and population controls. RESULTS: Three strongly correlated FCER1A polymorphisms were significantly associated with total and specific IgE levels as well as allergic sensitization. No associations were seen for FCER1B and FCER1G. After adjustment for FLG effects, a significant epistatic effect of the FCER1A variants rs10489854 and rs2511211 on eczema risk was detected. CONCLUSIONS: These results suggest that FCER1A variants by themselves and in combination influence IgE levels and act synergistically to influence eczema risk.


Subject(s)
Eczema/genetics , Epistasis, Genetic , Genetic Predisposition to Disease , Receptors, IgE/genetics , Adult , Aged , Eczema/blood , Eczema/immunology , Female , Filaggrin Proteins , Genome-Wide Association Study , Genotype , Humans , Hypersensitivity/blood , Hypersensitivity/genetics , Hypersensitivity/immunology , Immunoglobulin E/blood , Immunoglobulin E/immunology , Intermediate Filament Proteins/genetics , Intermediate Filament Proteins/immunology , Male , Middle Aged , Polymorphism, Single Nucleotide , Receptors, IgE/immunology , Risk Factors , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
14.
Gut ; 58(12): 1612-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19700435

ABSTRACT

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two cohorts of patients who received their first treatment with infliximab for refractory ulcerative colitis were studied. Response to infliximab was defined as endoscopic and histological healing. Total RNA from pre-treatment colonic mucosal biopsies was analysed with Affymetrix Human Genome U133 Plus 2.0 Arrays. Quantitative RT-PCR was used to confirm microarray data. RESULTS: For predicting response to infliximab treatment, pre-treatment colonic mucosal expression profiles were compared for responders and non-responders. Comparative analysis identified 179 differentially expressed probe sets in cohort A and 361 in cohort B with an overlap of 74 probe sets, representing 53 known genes, between both analyses. Comparative analysis of both cohorts combined, yielded 212 differentially expressed probe sets. The top five differentially expressed genes in a combined analysis of both cohorts were osteoprotegerin, stanniocalcin-1, prostaglandin-endoperoxide synthase 2, interleukin 13 receptor alpha 2 and interleukin 11. All proteins encoded by these genes are involved in the adaptive immune response. These markers separated responders from non-responders with 95% sensitivity and 85% specificity. CONCLUSION: Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-)response to infliximab. Further study of the pathways involved should allow a better understanding of the mechanisms of resistance to infliximab therapy in ulcerative colitis. ClinicalTrials.gov number, NCT00639821.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Colitis, Ulcerative/drug therapy , Gastrointestinal Agents/therapeutic use , Intestinal Mucosa/metabolism , Adult , Cohort Studies , Colitis, Ulcerative/genetics , Colitis, Ulcerative/metabolism , Colon/metabolism , Drug Resistance/genetics , Female , Gene Expression Profiling/methods , Humans , Infliximab , Male , Middle Aged , Oligonucleotide Array Sequence Analysis/methods , Prognosis , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction/methods , Treatment Outcome , Tumor Necrosis Factor-alpha/immunology , Young Adult
15.
Gut ; 58(4): 492-500, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18832518

ABSTRACT

BACKGROUND AND AIMS: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). METHODS: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. RESULTS: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. CONCLUSIONS: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Crohn Disease/drug therapy , Gastrointestinal Agents/therapeutic use , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Crohn Disease/surgery , Drug Administration Schedule , Drug Therapy, Combination , Drug Tolerance , Female , Follow-Up Studies , Gastrointestinal Agents/adverse effects , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Hospitalization/statistics & numerical data , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Infliximab , Male , Middle Aged , Prognosis , Prospective Studies , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
16.
Eur Respir J ; 32(2): 350-61, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18385169

ABSTRACT

Genetic association studies have related the tumour necrosis factor-alpha gene (TNFA) guanine to adenine substitution of nucleotide -308 (-308G>A) polymorphism to increased risk of asthma, but results are inconsistent. The aim of the present study was to test whether two single-nucleotide polymorphisms, of TNFA and of the lymphotoxin-alpha gene (LTA), are associated with asthma, bronchial hyperresponsiveness and atopy in adults, by combining the results of two large population-based multicentric studies and conducting a meta-analysis of previously published studies. The European Community Respiratory Health Survey (ECRHS) and Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) used comparable protocols, including questionnaires for respiratory symptoms and measures of lung function and atopy. DNA samples from 11,136 participants were genotyped at TNFA -308 and LTA 252. Logistic regression employing fixed and random effects models and nonparametric techniques were used. The prevalence of asthma was 6%. The TNFA -308G>A polymorphism was associated with increased asthma prevalence and with bronchial hyperresponsiveness. No consistent association was found for atopy. The LTA 252A>G polymorphism was not associated with any of the outcomes. A meta-analysis of 17 studies showed an increased asthma risk for the TNFA -308 adenine allele. The tumour necrosis factor-alpha gene nucleotide -308 polymorphism is associated with a moderately increased risk of asthma and bronchial hyperresponsiveness, but not with atopy. These results are supported by a meta-analysis of previously published studies.


Subject(s)
Asthma/genetics , Bronchial Hyperreactivity/genetics , Tumor Necrosis Factor-alpha/genetics , Adolescent , Adult , Alleles , Asthma/diagnosis , Asthma/epidemiology , Asthma/pathology , Bronchi/metabolism , Bronchi/pathology , Bronchial Hyperreactivity/diagnosis , Cohort Studies , Female , Genotype , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk , Tumor Necrosis Factor-alpha/physiology
17.
Ann Hum Genet ; 71(Pt 2): 141-51, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17096676

ABSTRACT

The high throughput of data arising from the complete sequence of the human genome has left statistical geneticists with a rich and extensive information source. The wide availability of software and the increase in computing power has improved the possibilities to access and process such data. One problem is incompleteness of the data: unobserved or partially observed data points due to technical reasons or reasons associated with the patient's status or erroneous measurements of phenotype or genotype, to name a few. When not properly accounted for, these sources of incompleteness may seriously jeopardize the credibility of results from analyses. In this paper we provide some perspectives on the occurrence and analysis of different forms of incomplete data in family-based genetic association testing.


Subject(s)
Genetics, Medical/statistics & numerical data , Data Interpretation, Statistical , Family , Female , Genotype , Haplotypes , Humans , Male , Models, Statistical
18.
Gut ; 53(7): 980-6, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15194648

ABSTRACT

BACKGROUND AND AIMS: Genome wide scans in inflammatory bowel disease (IBD) have indicated various susceptibility regions with replication of 16cen (IBD1), 12q (IBD2), 6p (IBD3), 14q11 (IBD4), and 3p21. As no linkage was previously found on IBD regions 3, 7, 12, and 16 in Flemish IBD families, a genome wide scan was performed to detect other susceptibility regions in this population. METHODS: A cohort of 149 IBD affected relative pairs, all recruited from the Northern Flemish part of Belgium, were genotyped using microsatellite markers at 12 cM intervals, and analysed by Genehunter non-parametric linkage software. All families were further genotyped for the three main Crohn's disease associated variants in the NOD2/CARD15 gene. RESULTS: Nominal evidence for linkage was observed on chromosomes 1 (D1S197: multipoint non-parametric linkage (NPL) score 2.57, p = 0.004; and at D1S305-D1S252: NPL 2.97, p = 0.001), 4q (D4S406: NPL 1.95, p = 0.03), 6q16 (D6S314: NPL 2.44, p = 0.007), 10p12 (D10S197: NPL 2.05, p = 0.02), 11q22 (D11S35-D11S927: NPL 1.95, p = 0.02) 14q11-12 (D14S80: NPL 2.41, p = 0.008), 20p12 (D20S192: NPL 2.7, p = 0.003), and Xq (DXS990: NPL 1.70, p = 0.04). A total of 51.4% of patients carried at least one NOD2/CARD15 variant. Furthermore, epistasis was observed between susceptibility regions 6q/10p and 20p/10p. CONCLUSION: Genome scanning in a Flemish IBD population found nominal evidence for linkage on 1p, 4q, 10p12, and 14q11, overlapping with other genome scan results, with linkage on 14q11-12 supporting the IBD4 locus. The results further show that epistasis is contributing to the complex model of IBD and indicate that population heterogeneity is not to be underestimated. Finally, NOD2/CARD15 is clearly implicated in the Flemish IBD population.


Subject(s)
Epistasis, Genetic , Genetic Predisposition to Disease , Genome, Human , Inflammatory Bowel Diseases/genetics , Chromosomes, Human, Pair 14/genetics , Female , Genetic Linkage , Genetic Markers , Humans , Inflammatory Bowel Diseases/ethnology , Male , Microsatellite Repeats , Statistics, Nonparametric
19.
Gut ; 53(7): 987-92, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15194649

ABSTRACT

BACKGROUND AND AIMS: Elicitation of an innate immune response to bacterial products is mediated through pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs) and the NODs. The recently characterised Asp299Gly polymorphism in the lipopolysaccharide (LPS) receptor TLR4 is associated with impaired LPS signalling and increased susceptibility to Gram negative infections. We sought to determine whether this polymorphism was associated with Crohn's disease (CD) and/or ulcerative colitis (UC). METHODS: Allele frequencies of the TLR4 Asp299Gly polymorphism and the three NOD2/CARD15 polymorphisms (Arg702Trp, Gly908Arg, and Leu1007fsinsC) were assessed in two independent cohorts of CD patients (cohort 1, n = 334; cohort 2, n = 114), in 163 UC patients, and in 140 controls. A transmission disequilibrium test (TDT) was then performed on 318 inflammatory bowel disease (IBD) trios. RESULTS: The allele frequency of the TLR4 Asp299Gly polymorphism was significantly higher in CD (cohort 1: 11% v 5%, odds ratio (OR) 2.31 (95% confidence interval (CI) 1.28-4.17), p = 0.004; and cohort 2: 12% v 5%, OR 2.45 (95% CI 1.24-4.81), p = 0.007) and UC patients (10% v 5%, OR 2.05 (95% CI 1.07-3.93), p = 0.027) compared with the control population. A TDT on 318 IBD trios demonstrated preferential transmission of the TLR4 Asp299Gly polymorphism from heterozygous parents to affected children (T/U: 68/34, p = 0.01). Carrying polymorphisms in both TLR4 and NOD2 was associated with a genotype relative risk (RR) of 4.7 compared with a RR of 2.6 and 2.5 for TLR4 and NOD2 variants separately. CONCLUSION: We have reported on a novel association of the TLR4 Asp299Gly polymorphism with both CD and UC. This finding further supports the genetic influence of PRRs in triggering IBD.


Subject(s)
Bacterial Infections/genetics , Colitis, Ulcerative/genetics , Crohn Disease/genetics , Intracellular Signaling Peptides and Proteins , Membrane Glycoproteins/genetics , Polymorphism, Genetic , Receptors, Cell Surface/genetics , Adolescent , Adult , Bacterial Infections/complications , Carrier Proteins/genetics , Colitis, Ulcerative/immunology , Colitis, Ulcerative/microbiology , Crohn Disease/immunology , Crohn Disease/microbiology , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Male , Nod2 Signaling Adaptor Protein , Toll-Like Receptor 4 , Toll-Like Receptors
20.
Eur J Cancer ; 40(7): 1021-30, 2004 May.
Article in English | MEDLINE | ID: mdl-15093577

ABSTRACT

The potential value of baseline health-related quality-of-life (HRQOL) and clinical factors in predicting prognosis was examined using data from an international randomised phase III trial which compared doxorubicin and paclitaxel with doxorubicin and cylophosphamide as first line chemotherapy in 275 women with metastatic breast cancer. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the related breast module (QLQ-BR23) were used to assess baseline HRQOL data. The Cox proportional-hazards regression model was used for both univariate and multivariate analyses of survival. In the univariate analyses, performance status (P<0.001) and number of sites involved (P=0.001) were the most important clinical prognostic factors. The HRQOL variables at baseline most strongly associated with longer survival were better appetite, physical and role functioning, as well as less fatigue (P<0.001). The final multivariate model retained performance status (P<0.001) and appetite loss (P=0.005) as the variables best predicting survival. Substantial loss of appetite was the only independent HRQOL factor predicting poor survival and was strongly correlated (/r/>0.5) with fatigue, role and physical functioning. In addition to known clinical factors, appetite loss appears to be a significant prognostic factor for survival in women with metastatic breast cancer. However, the mechanism underlying this association remains to be precisely defined in future studies.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Quality of Life , Adult , Aged , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Humans , Middle Aged , Neoplasm Metastasis/drug therapy , Paclitaxel/administration & dosage , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL